Tirzepatide: what to expect from your first dose to your maintenance phase

The decision before you: is the early discomfort worth the longer payoff?

Before the question becomes "how much will I lose?", it is usually "will the side effects put me off?". That is the real decision most people are weighing at the start. Tirzepatide's most common early effects are nausea, some queasiness after eating, and occasionally loose stools or constipation. These are not universal, but they are common enough that the prescribing schedule is deliberately gradual. The first pen is dosed at 2.5mg because the purpose of that month is adjustment, not treatment, the body learning to tolerate the medicine before the dose climbs.

If you are looking at the first week in particular, the experience varies considerably. Some people feel almost nothing; others notice appetite falling sharply from day two or three. Fatigue and mild headache are also reported in the early days. The NHS medicines page for tirzepatide notes these as recognised effects, and they are consistent with what the clinical trials recorded.

The practical question you are answering in week one is simpler than it sounds: can you eat less comfortably, and are the side effects manageable? For most people who stay on the medicine, the answer is yes. For a minority, titration needs to slow, something a prescriber can adjust. The decision to continue is, in that sense, rolling rather than once-and-for-all.

What happens between weeks two and twelve

By week two, most people notice appetite behaving differently. Food becomes less compelling. Portion sizes shrink, not through willpower but because fullness arrives earlier. Gastric emptying slows, which means meals last longer in the stomach, one of the mechanisms behind that shift. Some people find this strange at first; others describe it as the first time eating has felt genuinely manageable.

Weight loss in this phase tends to be gradual. A kilogram or two across the first month is a common experience; the rate picks up as the dose increases toward therapeutic levels. The titration schedule means the dose typically steps up every four weeks, guided by the prescriber. Understanding how long tirzepatide takes to work helps calibrate expectations: the first few weeks show early signs; the six-to-twelve-week window is where most people see sustained momentum.

It is also the phase where habits matter most. The medicine changes appetite biology; it does not change the environment around eating. People who build a protein-rich, fibre-adequate diet alongside treatment tend to report better energy and less muscle loss. A daily walk before the school run, or any structured movement, amplifies the metabolic shift. GLP-1 treatment is not a passive process.

The maintenance phase: what sustained tirzepatide use looks like

Once a person reaches their highest tolerated dose and weight has been stabilising for several months, the questions shift. How much has been lost? Is it being maintained? What happens if treatment stops? The longer experience on tirzepatide is that weight broadly returns without the medicine, because obesity has an underlying biology that the medicine manages rather than cures. That is not a reason to avoid treatment; it is useful context for the conversation with a prescriber about how long to continue.

The SURMOUNT-1 trial (which enrolled over 2,500 adults across its randomised groups and was published in the New England Journal of Medicine) recorded around 20–21% average body-weight reduction at 15mg over 72 weeks. Those figures come from a controlled trial setting; individual results vary. What people typically experience on Mounjaro in real-world use is broadly consistent with the trial direction, though the pace differs.

Side effects at maintenance doses tend to be less intrusive than in the titration phase, though they do not disappear entirely for everyone. The pancreatitis warning issued by the MHRA in January 2026 is worth knowing: severe or persistent stomach pain that reaches the back, with or without vomiting, requires prompt medical attention. You can report any suspected side effects via the MHRA's Yellow Card scheme, which also accepts reports about suspect sellers. For a full clinical picture of the medicine and its monitoring requirements, the NHS tirzepatide medicines page covers the verified detail.

Deciding whether tirzepatide is right for your situation

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. The full overview of Mounjaro covers eligibility in more detail.

The medicine is not recommended during pregnancy, breastfeeding, or if conception is planned. Women taking oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced; NHS guidance confirms this interaction for tirzepatide specifically. These are questions a prescriber works through with you at assessment, they are not reasons to avoid the conversation.

If you are weighing up where to start, the treatment overview gives a broader picture of licensed options. For information about how nume's process works from consultation through to prescription and delivery, the about-us page explains the clinical infrastructure behind it. And if you are ready to have your questions answered by a real prescriber rather than a page, a free consultation is the natural next step. A named clinician reviews every submission the same day, no algorithms involved.

One question worth considering before you book: how much of what you expected from tirzepatide was based on headlines, and how much on the actual trial data? The two are often further apart than people realise. Understanding that gap is part of what the consultation is for. Our clinical team see this regularly and find it a more useful starting point than almost any other.